Fampridine - MS Research Australia

Fampridine

Fampridine

Administration Route: Oral
Injection site:
Frequency: Twice daily
TGA approval date: 13 May 2011
PBS listed: No
Mechanism of action Fampridine is a formulation of 4-aminopyridine, a potassium channel blocker. It works by stopping potassium leaving nerve cells which have been damaged by MS so letting signals pass down the nerve more normally. Consequently, some people are able to walk better.
%reduction in relapse rate, impact of progression This is a symptomatic treatment
Pregnancy Category C
Safe in Pregnancy Suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects.
Breastfeeding (information predominatly from  LACTMED database) Fampridine is not recommended while breastfeeding
Monitoring requirements
Potential side effects (not a comprehensive list) Increased risk of urinary infections, headaches, feeling weak,anxiety, sore throat, nausea, vomiting, constipation, upset stomach, back pain, dizziness, feeling unsteady, tingling of the skin, minor shaking, worsening of facial nerve pain.
Manufacturer Biogen
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search